S-H Lee1, J-K Lee2, M-J Ahn1, D-W Kim2, J-M Sun1, B Keam2, T M Kim2, D S Heo2, J S Ahn1, Y-L Choi3, H-S Min4, Y K Jeon4, K Park1. 1. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul. 2. Department of Internal Medicine, Seoul National University Hospital, Seoul. 3. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul. 4. Department of Pathology, Seoul National University Hospital, Seoul, Korea.
Abstract
Background: Chromosomal rearrangements involving RET, which are found in about 1% of non-small cell lung cancer (NSCLC), define a unique molecular subset. We performed this study to examine the efficacy and safety of vandetanib 300 mg daily in this patient population. Patients and methods: This study was a multi-center, open-label, phase II clinical trial. Patients were enrolled if they had metastatic or recurrent NSCLC with a RET rearrangement, which was confirmed by fluorescence in situ hybridization, had progressive disease against platinum-based doublet chemotherapy, and had a performance status of 0-2. The primary endpoint was the objective response rate. Results: A total of 18 patients were enrolled in this study between July 2013 and October 2015. Patients were aged 35-71 years; three had a performance status of 2, and the majority were a heavily pretreated population (≥ two different previous chemotherapy regimens in 72% of the patients). Among the 17 evaluable patients, three had a partial response (objective response rate = 18%) and eight had a stable disease (disease control rate = 65%). Among these patients, the partial response or disease stabilization was durable for more than 6 months in eight patients. Vandetanib also showed a progression-free survival of 4.5 months, and an overall survival of 11.6 months during a median follow-up duration of 14 months. The safety profile was comparable with previous studies of vandetanib. Most vandetanib-related adverse events were mild with prevalent hypertension and rash (in >70% of patients). Grade 3 toxicity included hypertension (n = 3), QT prolongation (2), and elevation of aminotransferases (1), and as a consequence the dose was reduced in four patients. There were no adverse events associated with grade 4 or 5 toxicity. Conclusion: Vandetanib is moderately active in pretreated patients with advanced NSCLC-harboring RET rearrangements.
Background: Chromosomal rearrangements involving RET, which are found in about 1% of non-small cell lung cancer (NSCLC), define a unique molecular subset. We performed this study to examine the efficacy and safety of vandetanib 300 mg daily in this patient population. Patients and methods: This study was a multi-center, open-label, phase II clinical trial. Patients were enrolled if they had metastatic or recurrent NSCLC with a RET rearrangement, which was confirmed by fluorescence in situ hybridization, had progressive disease against platinum-based doublet chemotherapy, and had a performance status of 0-2. The primary endpoint was the objective response rate. Results: A total of 18 patients were enrolled in this study between July 2013 and October 2015. Patients were aged 35-71 years; three had a performance status of 2, and the majority were a heavily pretreated population (≥ two different previous chemotherapy regimens in 72% of the patients). Among the 17 evaluable patients, three had a partial response (objective response rate = 18%) and eight had a stable disease (disease control rate = 65%). Among these patients, the partial response or disease stabilization was durable for more than 6 months in eight patients. Vandetanib also showed a progression-free survival of 4.5 months, and an overall survival of 11.6 months during a median follow-up duration of 14 months. The safety profile was comparable with previous studies of vandetanib. Most vandetanib-related adverse events were mild with prevalent hypertension and rash (in >70% of patients). Grade 3 toxicity included hypertension (n = 3), QT prolongation (2), and elevation of aminotransferases (1), and as a consequence the dose was reduced in four patients. There were no adverse events associated with grade 4 or 5 toxicity. Conclusion: Vandetanib is moderately active in pretreated patients with advanced NSCLC-harboring RET rearrangements.
Authors: Oliver Gautschi; Julie Milia; Thomas Filleron; Juergen Wolf; David P Carbone; Dwight Owen; Ross Camidge; Vignhesh Narayanan; Robert C Doebele; Benjamin Besse; Jordi Remon-Masip; Pasi A Janne; Mark M Awad; Nir Peled; Chul-Cho Byoung; Daniel D Karp; Michael Van Den Heuvel; Heather A Wakelee; Joel W Neal; Tony S K Mok; James C H Yang; Sai-Hong Ignatius Ou; Georg Pall; Patrizia Froesch; Gérard Zalcman; David R Gandara; Jonathan W Riess; Vamsidhar Velcheti; Kristin Zeidler; Joachim Diebold; Martin Früh; Sebastian Michels; Isabelle Monnet; Sanjay Popat; Rafael Rosell; Niki Karachaliou; Sacha I Rothschild; Jin-Yuan Shih; Arne Warth; Thomas Muley; Florian Cabillic; Julien Mazières; Alexander Drilon Journal: J Clin Oncol Date: 2017-03-13 Impact factor: 44.544
Authors: Wafik S El-Deiry; Richard M Goldberg; Heinz-Josef Lenz; Anthony F Shields; Geoffrey T Gibney; Antoinette R Tan; Jubilee Brown; Burton Eisenberg; Elisabeth I Heath; Surasak Phuphanich; Edward Kim; Andrew J Brenner; John L Marshall Journal: CA Cancer J Clin Date: 2019-05-22 Impact factor: 508.702
Authors: Casey J N Mathison; Donatella Chianelli; Paul V Rucker; John Nelson; Jason Roland; Zhihong Huang; Yang Yang; Jiqing Jiang; Yun Feng Xie; Robert Epple; Badry Bursulaya; Christian Lee; Mu-Yun Gao; Jennifer Shaffer; Sergio Briones; Yelena Sarkisova; Anna Galkin; Lintong Li; Nanxin Li; Chun Li; Su Hua; Shailaja Kasibhatla; Jacqueline Kinyamu-Akunda; Rie Kikkawa; Valentina Molteni; John E Tellew Journal: ACS Med Chem Lett Date: 2020-02-12 Impact factor: 4.345
Authors: Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo Journal: Curr Oncol Rep Date: 2020-04-16 Impact factor: 5.075
Authors: Alexander Drilon; Siqing Fu; Manish R Patel; Marwan Fakih; Ding Wang; Anthony J Olszanski; Daniel Morgensztern; Stephen V Liu; Byoung Chul Cho; Lyudmila Bazhenova; Cristina P Rodriguez; Robert C Doebele; Antoinette Wozniak; Karen L Reckamp; Tara Seery; Petros Nikolinakos; Zheyi Hu; Jennifer W Oliver; Denise Trone; Katherine McArthur; Rupal Patel; Pratik S Multani; Myung-Ju Ahn Journal: Cancer Discov Date: 2018-11-28 Impact factor: 39.397